May 12, 2023 07:34 AM EDT
R&D

In pre­lim­i­nary read­out, GSK notch­es win for meningo­coc­cal vac­cine

Lei Lei Wu

News Reporter

GSK said its next-gen­er­a­tion meningo­coc­cal vac­cine is just as good as cur­rent­ly avail­able vac­cines Bexsero and Men­veo in peo­ple be­tween the ages of 10 and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times